<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02562352</url>
  </required_header>
  <id_info>
    <org_study_id>TAPER-001-19-Aug-15</org_study_id>
    <nct_id>NCT02562352</nct_id>
  </id_info>
  <brief_title>Team Approach to Polypharmacy Evaluation and Reduction</brief_title>
  <acronym>TAPER</acronym>
  <official_title>Team Approach to Polypharmacy Evaluation and Reduction: Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Labarge Optimal Aging Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>David Braley and Nancy Gordon Chair in Family Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RxISK</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In an aging population, most seniors suffer from multiple chronic conditions. When the number&#xD;
      of medications taken is ≥5 (polypharmacy), the burden of taking so many together can do more&#xD;
      harm than good. This study will test a program focused on medication reduction involving&#xD;
      patient, pharmacist and physician using current technology aimed at reducing the harms of&#xD;
      polypharmacy. Reducing the risk of adverse effects from drugs or the interactions between&#xD;
      them involves prioritizing the most important ones according to the patient's preference and&#xD;
      stopping those which may no longer be necessary. Reducing the dose also reduces the risk of&#xD;
      drug side effects. Patients, aged over 69 years taking ≥5 medications, will randomly receive&#xD;
      the program immediately or at 6 months. The program involves information gathering from the&#xD;
      patient, medication review with the pharmacist and then a consultation with the family doctor&#xD;
      focused on discontinuing/reducing the dose of medications where possible using a 'pause and&#xD;
      monitor' framework to assess the need for restart. An electronic program that detects drug&#xD;
      adverse effects and flags potentially inappropriate medications will be integrated into a&#xD;
      clinical pathway incorporating monitoring and follow up systems. This study will examine&#xD;
      effects on patient and health relevant outcome measures as well as patients' and clinicians'&#xD;
      experiences of the program. The results will be used to determine whether this system can be&#xD;
      implemented as part of routine preventative care in older adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized 1:1 to receive the intervention at study start or delayed&#xD;
      appointment 6 months later. The intervention includes initial baseline data collection from&#xD;
      the patient including data on demographics, medications, and illness characteristics. The&#xD;
      patient will then attend an appointment with a pharmacist to review medications appropriate&#xD;
      for discontinuation/dose reduction, after which the patient will meet with his/her family&#xD;
      physician to discuss patient preferences for discontinuation/dose reduction. Follow up&#xD;
      appointments will take place at one week, 3 months and 6 months (study end). Questionnaires&#xD;
      and a semi-structured interview will take place at the 6 month appointment. After six months,&#xD;
      the control group will be offered the intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">November 2019</completion_date>
  <primary_completion_date type="Actual">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful discontinuation (Difference in mean number of medications)</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in mean number of medications per patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (EQ-5D)</measure>
    <time_frame>6 months</time_frame>
    <description>EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional Status (Mini Nutritional Assessment Short-Form)</measure>
    <time_frame>6 months</time_frame>
    <description>Mini Nutritional Assessment Short-Form;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient experience of deprescribing (Thematic analysis of semi structured interviews)</measure>
    <time_frame>6 months</time_frame>
    <description>Thematic analysis of semi structured interviews</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Functional Capacity (Manty structured validated interview)</measure>
    <time_frame>6 months</time_frame>
    <description>Manty structured validated interview</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Falls (self report number of falls)</measure>
    <time_frame>6 months</time_frame>
    <description>self report number of falls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (patient self report or clinician report)</measure>
    <time_frame>6 months</time_frame>
    <description>patient self report or clinician report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Resource Utilization (Number of hospital admissions and emergency dept visits)</measure>
    <time_frame>6 months</time_frame>
    <description>Number of hospital admissions and emergency dept visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition (The Mini Mental Status Examination)</measure>
    <time_frame>6 months</time_frame>
    <description>The Mini Mental Status Examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue (Avlund Mob-T Scale)</measure>
    <time_frame>6 months</time_frame>
    <description>Avlund Mob-T Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Enablement (Patient Enablement Index)</measure>
    <time_frame>6 months</time_frame>
    <description>Patient Enablement Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Efficacy (Stanford Self-Efficacy Scale)</measure>
    <time_frame>6 months</time_frame>
    <description>Stanford Self-Efficacy Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient self report of change in quality of life/morbidity (Global Impression Scale)</measure>
    <time_frame>6 months</time_frame>
    <description>Global Impression Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Comorbidity</condition>
  <condition>Medication Therapy Management</condition>
  <arm_group>
    <arm_group_label>TAPER program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention arm is comprised of:&#xD;
Identification of medications that are appropriate for discontinuation/dose reduction.&#xD;
Linked pharmacist/family physician consultations with patient to discuss medication discontinuation/dose reduction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care as wait list control</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TAPER program</intervention_name>
    <description>Patients will be randomized to receive the TAPER program at study start or delayed intervention at 6 months.</description>
    <arm_group_label>TAPER program</arm_group_label>
    <other_name>Medication Discontinuation/Dose Reduction</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 70 years of age or older&#xD;
&#xD;
          -  Participating family doctor as most responsible provider&#xD;
&#xD;
          -  Patient of McMaster Family Health Team&#xD;
&#xD;
          -  Currently taking 5 or more medications&#xD;
&#xD;
          -  Have not had a recent comprehensive medication review&#xD;
&#xD;
          -  Patient consents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  English language or cognitive skills inadequate to understand and respond to rating&#xD;
             scales&#xD;
&#xD;
          -  Terminal illness or other circumstance precluding 13 month study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dee Mangin, MBChB, DPH, FRNZC, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8P 1H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 21, 2015</study_first_submitted>
  <study_first_submitted_qc>September 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2015</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>polypharmacy</keyword>
  <keyword>multimorbidity</keyword>
  <keyword>randomized controlled trial</keyword>
  <keyword>drug discontinuation</keyword>
  <keyword>patient preference</keyword>
  <keyword>eHealth</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

